Icotinib: activity and clinical application in Chinese patients with lung cancer
| Autor: | Qing He, Mei Li, Yong-Song Guan |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Drug
Oncology China medicine.medical_specialty Lung Neoplasms medicine.medical_treatment media_common.quotation_subject Angiogenesis Inhibitors Antineoplastic Agents Apoptosis Carcinoma Non-Small-Cell Lung Crown Ethers Internal medicine medicine Carcinoma Animals Humans Drug Interactions Pharmacology (medical) Neoplasm Metastasis Lung cancer Randomized Controlled Trials as Topic media_common Pharmacology Chemotherapy business.industry General Medicine medicine.disease Surgery ErbB Receptors Clinical trial Clinical Trials Phase III as Topic Tolerability Icotinib Quinazolines business Targeted therapy of lung cancer |
| Zdroj: | Expert Opinion on Pharmacotherapy. 15:717-728 |
| ISSN: | 1744-7666 1465-6566 |
| DOI: | 10.1517/14656566.2014.890183 |
| Popis: | Icotinib (BPI-2009H, Conmana) is a novel oral quinazoline compound that has proven survival benefit in Chinese patients with lung cancer, for which several therapies are currently available often with unsatisfactory results. Icotinib is the first self-developed small molecular drug in China for targeted therapy of lung cancer.The authors' experience in the clinical application of icotinib is reviewed in combination with related publications in the literature. Antitumor activities were observed in non-small-cell lung cancer and others in several recent studies. On 7 June 2011, icotinib was approved by the State Food and Drug Administration of China for the treatment of local advanced or metastatic non-small-cell lung cancer based on the results of a nationwide, of 27 centers, randomized, double-blind, double-modulated, parallel-controlled, Phase III trial with single agent icotinib in lung cancer patients after failure of chemotherapy.Icotinib is a generic drug. Compared to the other two commercially available EGFR tyrosine kinase inhibitors, gefitinib and erlotinib, icotinib is similar to them in chemical structure, mechanism of activity and therapeutic effects but less expensive. Better safety as well as a wider therapeutic window has also been proven in several Chinese studies. Future studies on cost effectiveness are warranted. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|